3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
1
Interventions
Dexamethasone
115
Lenalidomide
74
daratumumab
57
Bortezomib
52
carfilzomib
41
Calcium Dobesilate
36
pomalidomide
35
Cyclophosphamide
26
isatuximab
23
belantamab mafodotin
22
Specimen Handling
20
Biopsy
20
Magnetic Resonance Spectroscopy
17
dexamethasone acetate
13
dexamethasone 21-phosphate
13
auricularum
12
ixazomib
11
iberdomide
11
fludarabine
11
elotuzumab
11
selinexor
10
Melphalan
10
fludarabine phosphate
8
talquetamab
7
X-Rays
7
trametinib
6
nirogacestat
6
venetoclax
5
Thalidomide
5
Nuclear Medicine Department, Hospital
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Multiple Myeloma
×
4-fluorobenzoyl-TN-14003
×
Clear all
NCT03246529
2026-01-15
GENESIS
BioLineRx, Ltd.
Phase 3
Active not recruiting
180 enrolled
22 charts